Rossari Biotech Ltd
Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India. [1]
Their 3 main product categories are [2]:
- Home, personal care, and performance chemicals
- Textile specialty chemical
- Animal health and nutrition
The company has two R&D facilities, one at Silvassa manufacturing facility and a research lab at IIT Bombay. [3]
- Market Cap ₹ 3,803 Cr.
- Current Price ₹ 687
- High / Low ₹ 973 / 568
- Stock P/E 27.9
- Book Value ₹ 214
- Dividend Yield 0.07 %
- ROCE 15.8 %
- ROE 12.2 %
- Face Value ₹ 2.00
Pros
Cons
- Company has a low return on equity of 12.6% over last 3 years.
- Dividend payout has been low at 2.24% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Chemicals Industry: Chemicals
Part of Nifty Microcap 250 Nifty Total Market BSE SmallCap BSE Allcap BSE Commodities
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
516 | 600 | 709 | 1,483 | 1,656 | 1,831 | 2,080 | |
438 | 495 | 586 | 1,299 | 1,433 | 1,581 | 1,815 | |
Operating Profit | 78 | 105 | 124 | 184 | 223 | 250 | 265 |
OPM % | 15% | 17% | 17% | 12% | 13% | 14% | 13% |
1 | 4 | 9 | 13 | 6 | 8 | 5 | |
Interest | 3 | 4 | 3 | 13 | 22 | 19 | 18 |
Depreciation | 12 | 17 | 23 | 48 | 63 | 60 | 67 |
Profit before tax | 63 | 88 | 107 | 136 | 144 | 178 | 185 |
Tax % | 28% | 26% | 25% | 28% | 26% | 26% | 26% |
46 | 65 | 80 | 98 | 107 | 131 | 136 | |
EPS in Rs | 103.82 | 12.86 | 15.45 | 17.74 | 19.45 | 23.66 | 24.63 |
Dividend Payout % | 0% | 4% | 3% | 3% | 3% | 2% | 2% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 28% |
3 Years: | 12% |
TTM: | 14% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 16% |
3 Years: | 12% |
TTM: | 5% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -10% |
1 Year: | -12% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | 13% |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Equity Capital | 4 | 10 | 10 | 11 | 11 | 11 | 11 |
Reserves | 119 | 277 | 398 | 794 | 904 | 1,037 | 1,174 |
8 | 67 | 0 | 8 | 74 | 119 | 218 | |
118 | 118 | 152 | 442 | 375 | 401 | 493 | |
Total Liabilities | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,896 |
74 | 94 | 181 | 607 | 585 | 578 | 625 | |
CWIP | 3 | 22 | 0 | 1 | 16 | 47 | 140 |
Investments | 0 | 18 | 0 | 36 | 51 | 63 | 58 |
173 | 338 | 379 | 611 | 712 | 880 | 1,074 | |
Total Assets | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,896 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
71 | 57 | 48 | 29 | 152 | 43 | 137 | |
-37 | -190 | -37 | -299 | -181 | -103 | -184 | |
-29 | 157 | -25 | 292 | 61 | 16 | 65 | |
Net Cash Flow | 5 | 23 | -14 | 22 | 32 | -44 | 19 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Debtor Days | 61 | 57 | 74 | 75 | 78 | 85 | 83 |
Inventory Days | 59 | 57 | 75 | 63 | 59 | 80 | 90 |
Days Payable | 114 | 95 | 104 | 61 | 56 | 62 | 73 |
Cash Conversion Cycle | 6 | 19 | 46 | 76 | 80 | 103 | 101 |
Working Capital Days | 25 | 39 | 60 | 64 | 57 | 85 | 96 |
ROCE % | 38% | 29% | 24% | 18% | 18% | 16% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
6h - Audio recording of Q4 FY25 earnings call available on company's website.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
2d - Of Q4 FY 25 - Earnings Presentation.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2d - Q4 FY25 revenue Rs.579.6 Cr; FY25 Rs.2080.3 Cr; Rs.192 Cr capex announced; dividend Re.0.50/share
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Newspaper publication of extracts of Consolidated Audited Financial Results for the Quarter and Financial Year ended March 31, 2025.
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
25 Apr - FY25 audited results approved; 25% final dividend; ESOP grant and allotment; Rs.95 Cr capacity expansion approved.
Annual reports
Concalls
-
Apr 2025TranscriptNotesPPT
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Jan 2024Transcript PPT
-
Oct 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021Transcript PPT
-
Jul 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Oct 2020Transcript PPT
-
Aug 2020Transcript PPT
Product Segments
The company is one of India’s leading specialty chemicals manufacturer offering 4,280+ products across 3 verticals: [1]